parallel randomized trial
S003053
Type 2 diabetes (adults)S003053
Design
Conduct and analysis
Arms
| Arm | Treatment | Background | Randomized | Analyzed | Completed treatment |
|---|---|---|---|---|---|
| A1 | liraglutide Liraglutide | metformin and or sulfonylurea or DPP-4 inhibitor; lifestyle: standard | 16 | 16 | |
| A2 | Insulin glargine Insulin glargine | metformin and or sulfonylurea or DPP-4 inhibitor; lifestyle: standard | 15 | 15 |
Baseline characteristics
As printed in the trial reports or registry, per arm or for the whole trial.
| Characteristic | Statistic | Liraglutide A1 | Insulin glargine A2 |
|---|---|---|---|
| age | mean (years) | 61.1 | 59.5 |
| age | sd (years) | 8.3 | 12.3 |
| bmi | median (kg/m2) | 26.6 | 25.8 |
| bmi | q1 (kg/m2) | 23.6 | 24.2 |
| bmi | q3 (kg/m2) | 29.9 | 28.2 |
| hba1c | mean (percent) | 8.6 | 8.7 |
| hba1c | sd (percent) | 0.8 | 0.8 |
| metformin use | percent | 100 | 93.3 |
| other dpp4i use | percent | 43.8 | 66.7 |
| other male | percent | 75.0 | 46.7 |
| other sulfonylurea use | percent | 87.5 | 80.0 |
| sbp | mean (mmHg) | 136.0 | 126.4 |
| sbp | sd (mmHg) | 14.9 | 14.2 |
Results
4 adjudicated result lines, grouped by outcome. Open an outcome to see its values.
HbA1c change (2 lines; O01)
| Week | Arm | Statistic | Estimate | SE or SD | 95% CI | Events / N | Detail |
|---|---|---|---|---|---|---|---|
| 14 | A1 | change | -1.20 percent | -1.54 to -0.86 | 16 | not stated; other; R0022481:Table 3 | |
| 14 | A2 | change | -0.65 percent | -1.34 to 0.03 | 15 | not stated; other; R0022481:Table 3 |
Systolic blood pressure change (2 lines; O05)
| Week | Arm | Statistic | Estimate | SE or SD | 95% CI | Events / N | Detail |
|---|---|---|---|---|---|---|---|
| 14 | A1 | change | 0.3 mmHg | -11.9 to 12.5 | 16 | not stated; other; R0022481:Table 3 | |
| 14 | A2 | change | 4.9 mmHg | -5.1 to 14.9 | 15 | not stated; other; R0022481:Table 3 |